Novel pyrimidine-pyridine hybrids: Synthesis, cyclooxygenase inhibition, anti-inflammatory activity and ulcerogenic liability

Ashley, 2012, Inflammation: mechanisms, costs, and natural variation, Annu. Rev. Ecol. Evol. Syst., 43, 385, 10.1146/annurev-ecolsys-040212-092530 Kamm, 2002, Cellular fluid mechanics, Annu. Rev. Fluid Mech., 34, 211, 10.1146/annurev.fluid.34.082401.165302 Abrahão, 2011 M.I. Barnhart, C.A. Baechler, Endothelial cell physiology, perturbations and responses, Seminars in thrombosis and hemostasis, Copyright© 1978 by Thieme Medical Publishers, Inc., Ny, 1978, pp. 50–86. S. Green, R. Buchbinder, L. Barnsley, S. Hall, M. White, N. Smidt, W.J. Assendelft, Non‐steroidal anti‐inflammatory drugs (NSAIDs) for treating lateral elbow pain in adults, The Cochrane Library, (2001). Vane, 1998, Anti-inflammatory drugs and their mechanism of action, Inflamm. Res., 47, 78, 10.1007/s000110050284 Voilley, 2001, Nonsteroid anti-inflammatory drugs inhibit both the activity and the inflammation-induced expression of acid-sensing ion channels in nociceptors, J. Neurosci., 21, 8026, 10.1523/JNEUROSCI.21-20-08026.2001 Abdellatif, 2017, Nitric oxide-NASIDS donor prodrugs as hybrid safe anti-inflammatory agents, Curr. Topics Medi. Chem., 17, 941, 10.2174/1568026616666160927153435 Halter, 2001, Cyclooxygenase 2—implications on maintenance of gastric mucosal integrity and ulcer healing: controversial issues and perspectives, Gut, 49, 443, 10.1136/gut.49.3.443 Jackson, 2000, COX-2 selective nonsteroidal anti-inflammatory drugs, Drugs, 59, 1207, 10.2165/00003495-200059060-00001 Rao, 2008, Evolution of nonsteroidal anti-inflammatory drugs (NSAIDs): cyclooxygenase (COX) inhibition and beyond, J. Pharm. Pharmaceut. Sci., 11, 81 Coruzzi, 2007, Gastrointestinal safety of novel nonsteroidal antiinflammatory drugs: selective COX-2 inhibitors and beyond, Acta Bio Medica Atenei Parmensis, 78, 96 Lazzaroni, 2004, Gastrointestinal side-effects of traditional non-steroidal anti-inflammatory drugs and new formulations, Alimentary Pharmacol. Therap., 20, 48, 10.1111/j.1365-2036.2004.02037.x Vane, 1998, CYCLOOXYGENASES 1 AND 2, Ann. Rev. Pharmacol. Toxicol., 38, 97, 10.1146/annurev.pharmtox.38.1.97 Abdel-Tawab, 2009, Nonsteroidal anti-inflammatory drugs: a critical review on current concepts applied to reduce gastrointestinal toxicity, Curr. Med. Chem., 16, 2042, 10.2174/092986709788682209 Bertolini, 2002, Selective COX-2 inhibitors and dual acting anti-inflammatory drugs: critical remarks, Curr. Med. Chem., 9, 1033, 10.2174/0929867024606650 Chan, 2009, Do COX-2 inhibitors raise blood pressure more than nonselective NSAIDs and placebo? An updated meta-analysis, J. Hyperten., 27, 2332, 10.1097/HJH.0b013e3283310dc9 Wong, 2005, Cardiovascular hazard and non-steroidal anti-inflammatory drugs, Curr. Opinion Pharmacol., 5, 204, 10.1016/j.coph.2005.02.001 Andersohn, 2006, Cyclooxygenase-2 selective nonsteroidal anti-inflammatory drugs and the risk of ischemic stroke a nested case-control study, Stroke, 37, 1725, 10.1161/01.STR.0000226642.55207.94 Jones, 2008, Gastrointestinal and cardiovascular risks of nonsteroidal anti-inflammatory drugs, Am. J. Med., 121, 464, 10.1016/j.amjmed.2008.01.045 Mason, 2006, Rofecoxib increases susceptibility of human LDL and membrane lipids to oxidative damage: a mechanism of cardiotoxicity, J. Cardiovasc. Pharmacol., 47, S7, 10.1097/00005344-200605001-00003 Ghodsi, 2010, Design, synthesis and biological evaluation of new 2, 3-diarylquinoline derivatives as selective cyclooxygenase-2 inhibitors, Bioorgan. Med. Chem., 18, 1029, 10.1016/j.bmc.2009.12.060 Bekhit, 2003, Design and synthesis of some substituted 1H-pyrazolyl-thiazolo [4, 5-d] pyrimidines as anti-inflammatory–antimicrobial agents, Eur. J. Med. Chem., 38, 27, 10.1016/S0223-5234(02)00009-0 Tozkoparan, 1999, Synthesis and anti-inflammatory activities of some thiazolo [3, 2-a] pyrimidine derivatives, Il Farmaco, 54, 588, 10.1016/S0014-827X(99)00068-3 Sondhi, 2007, One pot synthesis of pyrimidine and bispyrimidine derivatives and their evaluation for anti-inflammatory and analgesic activities, Bioorgan. Med. Chem., 15, 3334, 10.1016/j.bmc.2007.03.028 Bahekar, 2004, Synthesis and anti-inflammatory activity of some [4, 6-(4-substituted aryl)-2-thioxo-1, 2, 3, 4-tetrahydro-pyrimidin-5-yl]-acetic acid derivatives, Bioorgan. Med. Chem. Lett., 14, 1733, 10.1016/j.bmcl.2004.01.039 Johnston, 2005, The anti-inflammatory action of methotrexate is not mediated by lymphocyte apoptosis, but by the suppression of activation and adhesion molecules, Clin. Immunol., 114, 154, 10.1016/j.clim.2004.09.001 Sondhi, 2009, Synthesis, anti-inflammatory and analgesic activity evaluation of some pyrimidine derivatives, Indian J. Chem., 49B, 273 Venu, 2008, Synthesis and anti-inflammatory activity of 2-(2-aroylaroxy)-4, 6-dimethoxy pyrimidines, Bioorgan. Med. Chem. Lett., 18, 4409, 10.1016/j.bmcl.2008.06.061 Amir, 2008, Synthesis and biological evaluation of some 4-(1H-indol-3-yl)-6-phenyl-1, 2, 3, 4-tetrahydropyrimidin-2-ones/thiones as potent anti-inflammatory agents, Acta Pharm., 58, 467, 10.2478/v10007-008-0028-x Pillai, 2003, Novel drug designing approach for dual inhibitors as anti-inflammatory agents: implication of pyridine template, Biochem. Biophys. Res. Commun., 301, 183, 10.1016/S0006-291X(02)02996-0 Amr, 2006, Anti-inflammatory profile of some synthesized heterocyclic pyridone and pyridine derivatives fused with steroidal structure, Bioorgan. Med. Chem., 14, 4341, 10.1016/j.bmc.2006.02.045 Girgis, 2007, Novel synthesis of [1]-benzothiepino [5, 4-b] pyridine-3-carbonitriles and their anti-inflammatory properties, Bioorgan. Med. Chem., 15, 2403, 10.1016/j.bmc.2007.01.015 K.F. McClure, M.A. Letavic, M.A. Dombroski, A.J. Duplantier, E.R. Laird, Triazolo-pyridines anti-inflammatory compounds, Google Patents, 2004. Ochiai, 2011, Phosphodiesterase inhibitors. Part 2: design, synthesis, and structure–activity relationships of dual PDE3/4-inhibitory pyrazolo [1, 5-a] pyridines with anti-inflammatory and bronchodilatory activity, Bioorgan. Med. Chem. Lett., 21, 5451, 10.1016/j.bmcl.2011.06.118 Chowdhury, 2008, Synthesis of new 4-[2-(4-methyl (amino) sulfonylphenyl)-5-trifluoromethyl-2H-pyrazol-3-yl]-1, 2, 3, 6-tetrahydropyridines: a search for novel nitric oxide donor anti-inflammatory agents, Bioorgan. Med. Chem., 16, 8882, 10.1016/j.bmc.2008.08.059 Helal, 2015, Synthesis, biological evaluation and molecular modeling of novel series of pyridine derivatives as anticancer, anti-inflammatory and analgesic agents, Spectrochim. Acta Part A: Mol. Biomol. Spectrosc., 135, 764, 10.1016/j.saa.2014.06.145 Chowdhury, 2009, Synthesis of celecoxib analogues possessing a N-difluoromethyl-1, 2-dihydropyrid-2-one 5-lipoxygenase pharmacophore: biological evaluation as dual inhibitors of cyclooxygenases and 5-lipoxygenase with anti-inflammatory activity, J. Med. Chem., 52, 1525, 10.1021/jm8015188 Bakr, 2016, Synthesis, cyclooxygenase inhibition, anti-inflammatory evaluation and ulcerogenic liability of new 1-phenylpyrazolo [3, 4-d] pyrimidine derivatives, J. Enzyme Inhib. Med. Chem., 31, 6, 10.1080/14756366.2016.1186018 Abdelgawad, 2017, Design, synthesis and biological evaluation of some novel benzothiazole/benzoxazole and/or benzimidazole derivatives incorporating a pyrazole scaffold as antiproliferative agents, Bioorg. Chem., 74, 82, 10.1016/j.bioorg.2017.07.007 Banerjee, 2016, Design, synthesis, evaluation and molecular modelling studies of some novel 5, 6-diphenyl-1, 2, 4-triazin-3 (2H)-ones bearing five-member heterocyclic moieties as potential COX-2 inhibitors: a hybrid pharmacophore approach, Bioorgan. Chem., 69, 102, 10.1016/j.bioorg.2016.10.003 Youssif, 2004, 6-Aminouracils as precursors for the syntheses of fused di-and tricyclic pyrimidines, J. Chem. Res., 2004, 341, 10.3184/0308234041639683 K. Abdellatif, R. Bakr, A. Mehany, Synthesis, EGFR inhibition and anti-cancer activity of new 3, 6-dimethyl-1-phenyl-4-(substituted-methoxy) pyrazolo [3, 4-d] pyrimidine derivatives, Anti-cancer agents in medicinal chemistry, Anti-Cancer Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry - Anti-Cancer Agents), 17 (2017), 1389–1400. Naeimi, 2017, Sonochemical synthesis of pyrido [2, 3-d: 6, 5-d′]-dipyrimidines catalyzed by [HNMP]+[HSO4]− and their antimicrobial activity studies, J. Antibiotics, 70, 845, 10.1038/ja.2017.47 Naeimi, 2016, Iron (III)-doped, ionic liquid matrix-immobilized, mesoporous silica nanoparticles: application as recyclable catalyst for synthesis of pyrimidines in water, Microporous Mesoporous Mater., 227, 23, 10.1016/j.micromeso.2016.02.036 Mahmoud, 2009, A facile synthesis and heteroannulation of pyrido [2, 3-d] pyrimidine and related heterocyclic systems, J. Chem. Res., 2009, 612, 10.3184/030823409X12523324765777 Abdelgawad, 2017, Discovery of a COX-2 selective inhibitor hit with anti-inflammatory activity and gastric ulcer protective effect, Future Med. Chem., 9, 1899, 10.4155/fmc-2017-0115 Cho, 1979, Cholinergic-mediated gastric mast cell degranulation with subsequent histamine H1-and H2-receptor activation in stress ulceration in rats, Eur. J. Pharmacol., 55, 23, 10.1016/0014-2999(79)90144-4